Piecuch Jerzy, Rudzki Marek, Orkisz Witold, Swietochowska Elzbieta, Wielkoszyński Tomasz, Waniczek Dariusz, Arendt Jerzy, Sosada Krystyn, Zurawiński Wojciech, Ładny Jerzy Robert
Department of General and Bariatric Surgery, Medical University of Silesia, Zabrze, Poland.
Hepatogastroenterology. 2008 Jan-Feb;55(81):258-61.
BACKGROUND/AIMS: Pancreatic cancer constitutes a difficult diagnostic and therapeutic problem. It remains the fourth cause of death among gastrointestinal malignancies. The present study aimed to investigate whether neopterin can be used as a significant marker in pancreatic cancer and to establish any possible relationships between serum neopterin levels and the differentiation between chronic pancreatitis, pancreatic cancer, and acute pancreatitis.
The research was done on a group of 65 patients with a diagnosed pancreatic tumor and on a group of 21 patients with a diagnosed acute pancreatitis. Serum neopterin concentration was determined in all patients on the first day of hospitalization.
Based on intraoperative and postoperative histopathological findings, pancreatic cancer was diagnosed in 42 patients and chronic pancreatitis in 23 patients. Neopterin concentrations in pancreatic cancer patients, chronic pancreatitis patients, and acute pancreatitis patients were 13.01-29.64 nmol/L (mean 18.16), 0.95-11.81 nmol/L (mean 6.52), and 9.64-25.0 nmol/L (mean 13.61), respectively. Mean neopterin levels in pancreatic cancer and acute pancreatitis patients were higher than the accepted norm (norm<10 nmol/L). Serum neopterin concentrations in patients with chronic pancreatitis remained within the norm.
In our opinion, neopterin might be a promising factor of differentiation between pancreatic tumors. However, the use of neopterin as a nonspecific tumor marker requires further studies.
背景/目的：胰腺癌是一个诊断和治疗难题。它仍是胃肠道恶性肿瘤中第四大致死原因。本研究旨在探讨新蝶呤是否可作为胰腺癌的重要标志物，并确定血清新蝶呤水平与慢性胰腺炎、胰腺癌和急性胰腺炎之间的鉴别诊断是否存在任何可能的关系。
对一组65例确诊为胰腺肿瘤的患者和一组21例确诊为急性胰腺炎的患者进行了研究。在所有患者住院的第一天测定血清新蝶呤浓度。
根据术中及术后组织病理学检查结果，42例诊断为胰腺癌，23例诊断为慢性胰腺炎。胰腺癌患者、慢性胰腺炎患者和急性胰腺炎患者的新蝶呤浓度分别为13.01 - 29.64 nmol/L（平均18.16）、0.95 - 11.81 nmol/L（平均6.52）和9.64 - 25.0 nmol/L（平均13.61）。胰腺癌和急性胰腺炎患者的新蝶呤平均水平高于公认的正常范围（正常范围<10 nmol/L）。慢性胰腺炎患者的血清新蝶呤浓度仍在正常范围内。
我们认为，新蝶呤可能是胰腺肿瘤鉴别诊断的一个有前景的因素。然而，将新蝶呤用作非特异性肿瘤标志物还需要进一步研究。
